PA) - Daniel Rader, MD, a specialist in preventive
cardiovascular medicine at the University of Pennsylvania
School of Medicine and University of Pennsylvania
Health System (UPHS), has been selected to direct a prestigious
Freedom to Discover Unrestricted Biomedical Research Grant
awarded to the University of Pennsylvania School of Medicine by
Rader is one of two scientists in the cardiovascular area to be
granted this honor in 2006; other grant areas include: cancer, nutrition,
neuroscience, infectious disease, metabolic diseases, and synthetic
organic chemistry. A total of $6 million is being given to support
cutting-edge biomedical research at twelve institutions around the
Rader, a physician-scientist, is a leader in the field of preventive
cardiovascular medicine, cholesterol metabolism and atherosclerosis.
He is recognized for his translational research in applying basic
research in pathways of cholesterol metabolism and atherosclerosis
to the development of new therapeutic approaches to reduce heart
disease risk. He is especially well known for his work in novel
approaches to boosting HDL (good cholesterol) levels and function.
At Penn, Rader directs the General Clinical Research Center, is
Associate Director of the Institute for Translational Medicine and
Therapeutics, and is Director of Penn’s Lipid/Atherosclerosis/Cardiovascular
Metabolism Research Unit of the Cardiovascular Institute and the
Institute for Diabetes, Obesity and Metabolism. Clinically, he is
Director of Preventive Cardiovascular Medicine at UPHS and recognized
as an outstanding clinician.
In commenting on Rader’s selection, Michael Parmacek,
MD, Chief of Cardiovascular Medicine at Penn, noted, “This
honor is well deserved and recognizes the many significant contributions
that Dr. Rader has made over the past decade related to the prevention
of heart disease. Dr. Rader is a role model for other researchers
by demonstrating that it is possible to directly translate basic
scientific discoveries into novel therapies for cardiovascular disease.”
The Freedom to Discover Award includes $100,000 per year for five
years to use flexibly in support of Dr Rader's research program.
"This research money will enable us to try new approaches to
targeting HDL for therapeutic purposes, a key step in our goal of
preventing and reversing heart disease," said Rader.
PENN Medicine is a $2.9 billion enterprise
dedicated to the related missions of medical education, biomedical
research, and high-quality patient care. PENN Medicine consists
of the University of Pennsylvania School of Medicine (founded in
1765 as the nation's first medical school) and the University of
Pennsylvania Health System.
Penn's School of Medicine is ranked #2 in the nation for receipt
of NIH research funds; and ranked #3 in the nation in U.S.News &
World Report's most recent ranking of top research-oriented medical
schools. Supporting 1,400 fulltime faculty and 700 students, the
School of Medicine is recognized worldwide for its superior education
and training of the next generation of physician-scientists and
leaders of academic medicine.
The University of Pennsylvania Health System includes three
hospitals [Hospital of the University of Pennsylvania, which is
consistently ranked one of the nation's few "Honor Roll"
hospitals by U.S.News & World Report; Pennsylvania Hospital,
the nation's first hospital; and Penn Presbyterian Medical Center];
a faculty practice plan; a primary-care provider network; two multispecialty
satellite facilities; and home care and hospice.